Emergent BioSolutions | EBS - Equity Capital And Reserves


Emergent BioSolutions reported $649.3M in Equity Capital and Reserves for its fiscal quarter ending in December of 2023.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.39B 80.88M Sep/2026
Akebia Therapeutics USD 20.37M 4.65M Sep/2026
ALKERMES USD 1.86B 56.17M Sep/2026
Alnylam Pharmaceuticals USD 3.6B 2.25B Sep/2026
Amarin USD 444.41M 796K Sep/2026
ANI Pharmaceuticals USD 637.11M 39.9M Sep/2026
BioMarin Pharmaceutical USD 6.26B 65.66M Sep/2026
Coherus Biosciences USD 60.84M 17.78M Jun/2026
Emergent BioSolutions USD 649.3M 47.9M Dec/2023
Exelixis USD 1.83B 9.93M Sep/2026
Glaxosmithkline GBP 18.36B 940M Sep/2026
Heron Therapeutics USD 6.91M 2.23M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
Ironwood Pharmaceuticals USD -97.19M 64.65M Sep/2026
Lexicon Pharmaceuticals USD 202.86M 95.32M Mar/2026
Lonza CHF 9.13B 513M Dec/2025
Merck USD 44.89B 2.96B Sep/2026
Moderna USD 6.84B 76M Sep/2026
Myriad Genetics USD 303.9M 33.5M Jun/2026
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Neurocrine Biosciences USD 3.88B 185.1M Sep/2026
Pacira USD 712.32M 40.34M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
PTC Therapeutics USD -191.21M 25.85M Sep/2026
Sanofi EUR 72.88B 3.31B Sep/2026
Sarepta Therapeutics USD 1.53B 1.06M Sep/2026
United Therapeutics USD 6.28B 124.3M Sep/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025